IL305714A - Minimal nephrin factor - Google Patents
Minimal nephrin factorInfo
- Publication number
- IL305714A IL305714A IL305714A IL30571423A IL305714A IL 305714 A IL305714 A IL 305714A IL 305714 A IL305714 A IL 305714A IL 30571423 A IL30571423 A IL 30571423A IL 305714 A IL305714 A IL 305714A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- promoter
- nucleotide sequence
- vector
- identity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2021/050633 WO2021181118A1 (en) | 2020-03-12 | 2021-03-12 | Gene therapy |
| GBGB2103470.7A GB202103470D0 (en) | 2021-03-12 | 2021-03-12 | Promoter |
| PCT/GB2021/051668 WO2022003357A1 (en) | 2020-06-30 | 2021-06-30 | Vector |
| PCT/GB2022/050649 WO2022189811A1 (en) | 2021-03-12 | 2022-03-14 | Minimal nephrin promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305714A true IL305714A (en) | 2023-11-01 |
Family
ID=75623235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305714A IL305714A (en) | 2021-03-12 | 2022-03-14 | Minimal nephrin factor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20250283072A1 (https=) |
| EP (2) | EP4722371A2 (https=) |
| JP (1) | JP2024509316A (https=) |
| KR (1) | KR20230161459A (https=) |
| CN (1) | CN117377770A (https=) |
| AU (1) | AU2022235209A1 (https=) |
| BR (1) | BR112023018362A2 (https=) |
| CA (1) | CA3211566A1 (https=) |
| DK (1) | DK4305181T3 (https=) |
| ES (1) | ES3056304T3 (https=) |
| FI (1) | FI4305181T3 (https=) |
| GB (1) | GB202103470D0 (https=) |
| HR (1) | HRP20251561T1 (https=) |
| IL (1) | IL305714A (https=) |
| MX (1) | MX2023010573A (https=) |
| PL (1) | PL4305181T3 (https=) |
| PT (1) | PT4305181T (https=) |
| WO (1) | WO2022189811A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003109D0 (en) * | 2020-03-04 | 2020-04-15 | Univ Bristol | Gene therapy |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| GB202217332D0 (en) * | 2022-11-18 | 2023-01-04 | Univ Bristol | Methods |
| EP4397976A1 (en) * | 2023-01-09 | 2024-07-10 | x-kidney diagnostics GmbH | Biomarkers for the pre-clinical and/or early-stage detection and/or diagnosis of kidney diseases |
| GB202309909D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Regulatory elements |
| GB202309908D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases |
| GB202309913D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome |
| GB202309914D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Promoters |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| US8852936B2 (en) | 2012-09-21 | 2014-10-07 | Laurantis Pharma Oy | Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery |
| TW201506036A (zh) | 2013-08-14 | 2015-02-16 | Laurantis Pharma Oy | Vegf-c及ccbe1之治療用途 |
| GB201900702D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
-
2021
- 2021-03-12 GB GBGB2103470.7A patent/GB202103470D0/en not_active Ceased
-
2022
- 2022-03-14 CA CA3211566A patent/CA3211566A1/en active Pending
- 2022-03-14 AU AU2022235209A patent/AU2022235209A1/en active Pending
- 2022-03-14 BR BR112023018362A patent/BR112023018362A2/pt unknown
- 2022-03-14 EP EP25181596.5A patent/EP4722371A2/en active Pending
- 2022-03-14 PT PT227107141T patent/PT4305181T/pt unknown
- 2022-03-14 EP EP22710714.1A patent/EP4305181B1/en active Active
- 2022-03-14 DK DK22710714.1T patent/DK4305181T3/da active
- 2022-03-14 FI FIEP22710714.1T patent/FI4305181T3/fi active
- 2022-03-14 US US18/280,699 patent/US20250283072A1/en active Pending
- 2022-03-14 JP JP2023555709A patent/JP2024509316A/ja active Pending
- 2022-03-14 PL PL22710714.1T patent/PL4305181T3/pl unknown
- 2022-03-14 ES ES22710714T patent/ES3056304T3/es active Active
- 2022-03-14 KR KR1020237034581A patent/KR20230161459A/ko active Pending
- 2022-03-14 WO PCT/GB2022/050649 patent/WO2022189811A1/en not_active Ceased
- 2022-03-14 IL IL305714A patent/IL305714A/en unknown
- 2022-03-14 MX MX2023010573A patent/MX2023010573A/es unknown
- 2022-03-14 CN CN202280034399.8A patent/CN117377770A/zh active Pending
- 2022-03-14 HR HRP20251561TT patent/HRP20251561T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250283072A1 (en) | 2025-09-11 |
| CN117377770A (zh) | 2024-01-09 |
| MX2023010573A (es) | 2023-11-03 |
| AU2022235209A1 (en) | 2023-10-05 |
| CA3211566A1 (en) | 2022-09-15 |
| KR20230161459A (ko) | 2023-11-27 |
| PL4305181T3 (pl) | 2026-01-26 |
| BR112023018362A2 (pt) | 2023-12-05 |
| ES3056304T3 (en) | 2026-02-19 |
| EP4722371A2 (en) | 2026-04-08 |
| PT4305181T (pt) | 2025-12-04 |
| HRP20251561T1 (hr) | 2026-02-13 |
| JP2024509316A (ja) | 2024-02-29 |
| FI4305181T3 (fi) | 2025-12-12 |
| GB202103470D0 (en) | 2021-04-28 |
| EP4305181B1 (en) | 2025-11-05 |
| DK4305181T3 (en) | 2025-12-15 |
| EP4305181A1 (en) | 2024-01-17 |
| WO2022189811A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4305181B1 (en) | Minimal nephrin promoter | |
| CN106029891B (zh) | 病毒载体生产系统 | |
| JP2023536008A (ja) | ベクター | |
| US20260053952A1 (en) | Methods of delivering a viral vector to a kidney | |
| AU2024306574A1 (en) | Regulatory elements | |
| JP2024517957A (ja) | ベクター系 | |
| WO2025003703A1 (en) | Promoters | |
| RU2854890C1 (ru) | Вектор | |
| EP4689135A1 (en) | Promoter | |
| WO2026074284A1 (en) | Methods of transducing podocytes | |
| WO2025003704A2 (en) | Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases |